FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * Peterson Caryn 2. Date of Event Requiring Statement (MM/DD/YYYY)
4/16/2021 

3. Issuer Name and Ticker or Trading Symbol Gossamer Bio, Inc. [GOSS]
(Last)       (First)       (Middle)
3013 SCIENCE PARK ROAD
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director                          _____ 10% Owner
___X___ Officer (give title below)        _____ Other (specify below)
EVP, Regulatory Affairs /
(Street)
SAN DIEGO, CA 92121      
(City)             (State)             (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)
 

6. Individual or Joint/Group Filing(Check Applicable Line)_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock  64008 (1) D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy)   (2) 5/21/2028  Common Stock  86444.0  $2.61  D   
Stock Option (Right to Buy)   (3) 12/10/2028  Common Stock  48888.0  $10.71  D   
Stock Option (Right to Buy)   (4) 3/25/2029  Common Stock  48500.0  $22.1  D   
Stock Option (Right to Buy)   (5) 12/23/2029  Common Stock  13750.0  $16.4  D   
Stock Option (Right to Buy)   (6) 2/14/2030  Common Stock  34175.0  $14.55  D   
Stock Option (Right to Buy)   (7) 2/25/2031  Common Stock  28250.0  $9.79  D   

Explanation of Responses:
(1)  Includes 54,427 restricted stock unit awards, which will vest in accordance with the terms of each award and subject to the Reporting Person's continuous service to the Issuer on each vesting date.
(2)  64,840 shares subject to the option have vested and are fully exerciseable and 1/48th of the total number of shares subject to the option vest on April 21, 2021 and the last day of each one-month period thereafter through May 21, 2022, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.
(3)  28,540 shares subject to the option have vested and are fully exerciseable and 1/48th of the total number of shares subject to the option vest on May 10, 2021 and the last day of each one-month period thereafter through December 10, 2022, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.
(4)  24,250 shares subject to the option have vested and are fully exerciseable and 1/48th of the total number of shares subject to the option vest on April 25, 2021 and the last day of each one-month period thereafter through March 25, 2023, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.
(5)  4,296 shares subject to the option have vested and are fully exerciseable and 1/48th of the total number of shares subject to the option vest on April 23, 2021 and the last day of each one-month period thereafter through December 23, 2023, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.
(6)  9,967 shares subject to the option have vested and are fully exerciseable and 1/48th of the total number of shares subject to the option vest on May 14, 2021 and the last day of each one-month period thereafter through February 14, 2024, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.
(7)  25% of the total number of shares subject to the option will vest on February 25, 2022 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.

Remarks:
Exhibit 24 - Power of Attorney

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Peterson Caryn
3013 SCIENCE PARK ROAD
SAN DIEGO, CA 92121


EVP, Regulatory Affairs

Signatures
/s/ Jeff Boerneke, Attorney-in-Fact 4/20/2021
**Signature of Reporting Person Date
Gossamer Bio (NASDAQ:GOSS)
Historical Stock Chart
From Sep 2021 to Oct 2021 Click Here for more Gossamer Bio Charts.
Gossamer Bio (NASDAQ:GOSS)
Historical Stock Chart
From Oct 2020 to Oct 2021 Click Here for more Gossamer Bio Charts.